Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Iván Henríquez,
Mack Roach,
Todd M. Morgan,
Alberto Bossi,
Junior A. Gómez,
Oscar Abuchaibe,
Felipe Couñago
Affiliations
Iván Henríquez
Department of Radiation Oncology, Hospital Universitario Sant Joan, 43204 Reus, Spain
Mack Roach
UCSF Helen Diller Family Comprehensive Cancer Center, Department of Radiation Oncology, San Francisco, CA 94143, USA
Todd M. Morgan
Rogel Cancer Center, Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA
Alberto Bossi
Prostate Brachytherapy Unit, Department of Radiation Oncology, Genito Urinary Oncology, Goustave Roussy, 94805 Paris, France
Junior A. Gómez
Department of Radiation Oncology, Hospital Universitario Sant Joan, 43204 Reus, Spain
Oscar Abuchaibe
Virgilio Galvis Ramirez Cancer Centre, Department of Radiation Oncology, Bucaramanga 681004, Colombia
Felipe Couñago
Department of Radiation Oncology, Clinical Department, Faculty of Biomedicine, Hospital Universitario Quirónsalud Madrid, Hospital La Luz, Universidad Europea, 28223 Madrid, Spain
Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous wide range of molecular tumor behavior and a high risk of progression. Early detection and treatment are therefore crucial in these patients. Treatment has improved drastically in recent years and many novel therapeutic agents are currently under investigation. However, due to the rapidly changing therapeutic landscape in mCRPC, it is difficult for clinicians to keep up to date with the latest innovations in this area. In the present narrative review, we discuss the current and emerging therapies for mCRPC as well as the clinical and molecular factors that can help predict which patients are most likely to benefit from these novel agents.
